BioSpace News Archive

BioMark’s blood-based metabolomic biomarker panel clinically improved early-stage lung cancer detection through stage shifting.

Paragon operates an industry-leading geochemistry lab strategically located near Reno, Nevada, at the heart of one of the world’s most active mining regions

Mustard plant-based development programs to focus on soil and microbiome health, nutrient and water use efficiencies, and plant yields.

NervGen Pharma Corp. (TSXV: NGEN) (OTCQX: NGENF) (“NervGen” or the “Company”), a clinical stage biotech company dedicated to developing innovative solutions for the treatment of nervous system damage,

The American Cancer Society and Color Health announced a partnership that will provide convenient, accessible, and comprehensive cancer prevention and screening solutions for the highest-burden cancers including breast, prostate, lung, cervical, and colorectal for more than 150 million Americans who receive health care through either their employer or union.

Ellipses Pharma (“Ellipses”) today announces its intention to expedite further global clinical development of the next generation selective RET inhibitor (SRI) EP0031/A400 following the publication of ‘very encouraging’ clinical data.

Oxurion NV, a biopharmaceutical company developing next generation standard of care ophthalmic therapies, with clinical stage assets in vascular retinal disorders, held its extraordinary shareholders’ meeting on May 22, 2023.

Gilead Sciences, Inc. (Nasdaq: GILD) today announced longer-term overall survival (OS) results from the Phase 3 TROPiCS-02 study evaluating Trodelvy® (sacituzumab govitecan-hziy) versus comparator chemotherapy (physicians’ choice of chemotherapy, TPC) in patients with HR+/HER2- (IHC0, IHC1+, IHC2+/ISH-) metastatic breast cancer who received endocrine-based therapies and at least two chemotherapies.

The Janssen Pharmaceutical Companies of Johnson & Johnson announced long-term data from the pivotal Phase 1/2 MajesTEC-1 study showing the sustained efficacy and safety of TECVAYLI® in the treatment of patients with relapsed or refractory multiple myeloma who are triple-class exposed and previously received treatment with three or more prior lines of therapy.

A consortium of eight academic and industry partners is advancing the development of a universal influenza vaccine with a €7.6 million grant from the European Union.